1+ week, 3+ day ago   (395+ words) The Clinical Trial Vanguard PMV Pharma’s Rezatapopt Achieves 44% Response Rate in TP53 Y220C Ovarian Cancer A 44% objective response rate in heavily pretreated ovarian cancer patients is the number PMV Pharmaceuticals is betting its regulatory future on. Updated interim data from the Phase…...

3+ mon, 4+ week ago   (412+ words) The Clinical Trial Vanguard Biogen’s Diranersen Shows Tau Biomarker Reduction in Phase 2 Alzheimer’s Study Tau reduction without a primary endpoint hit is either a trial failure or the most important proof-of-concept in Alzheimer’s drug development this decade — and Biogen’s Phase…...

3+ mon, 4+ week ago   (396+ words) The Clinical Trial Vanguard Voyager’s VY1706 cuts tau 64% in primates with no safety issues A 64% reduction in tau protein across key brain regions of non-human primates, achieved with a single intravenous dose and zero adverse histopathological findings at the highest tested…...

5+ mon, 2+ week ago   (645+ words) The Clinical Trial Vanguard One Biomarker, Two Diseases: The p-tau Signal That Just Complicated Your Stratification Strategy Pull up the enrollment criteria for any Phase 2 or Phase 3 Alzheimer’s trial running today. Somewhere in the inclusion criteria, you will find a p-tau…...